MiMedx Group Bets on Surgery Growth and Sanara Deal as Wound Care Struggles
MIMEDX to Participate in Upcoming Investor Conferences
MiMedx (MDXG) Stock Slips As Q3 Earnings Leave Profit Questions
MiMedx Group, Inc. Q3 2026 Earnings Call Summary
MiMedx (MDXG) Q3 2026 Earnings Call Transcript
MiMedx: Q3 Earnings Snapshot
MIMEDX Announces Third Quarter 2026 Operating & Financial Results
MIMEDX Announces $25 Million Patent License Agreement
MiMedx Group, Inc. (MDXG) Q3 2026 Earnings Call Transcript
MiMedx Group Q3 2026 Earnings Call Transcript
MiMedx Group Lowers FY2026 Sales Guidance from $260.000M-$290.000M to $250.000M-$260.000M vs $267.018M Est
MiMedx Group Q3 Adj. EPS $(0.01), Inline, Sales $62.283M Miss $68.553M Estimate
MiMedx Group Inks $25M License Deal With Undisclosed Wound Care Competitor To Settle Allegations Of Infringement Of MiMedx's Patents
MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months
MiMedx, Sanara Receive U.S. Federal Trading Commission Second Request For Additional Information, Documentary Materials For Proposed Business Combination
MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter
MiMedx Group Announces U.S. Court Issues Favorable Ruling In Co.'s Litigation Against FDA's Regulatory Classification Of AXIOFILL
Craig-Hallum Maintains Buy on MiMedx Group, Raises Price Target to $8
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.